Novo Nordisk announced on December 12, 2025 that its GLP‑1 drug Ozempic will be available in India for a 0.25 mg dose at a weekly price of $24.35, a price that is more than ten times lower than the U.S. list price of roughly $100 per week. The launch is limited to type‑2 diabetes treatment, as the company has obtained regulatory approval for that indication in India.
India is the world’s second‑largest market for diabetes and obesity, with an estimated 70 million people living with type‑2 diabetes and a rapidly growing obesity population. By entering this market, Novo Nordisk aims to capture a significant share of patients who previously could not afford branded GLP‑1 therapy, thereby expanding its global footprint and creating a new revenue stream in a high‑growth region.
The aggressive pricing strategy is designed to pre‑empt the entry of domestic generics that will become available once semaglutide’s patent expires in March 2026. By pricing Ozempic at $24 a week, Novo Nordisk positions itself ahead of competitors such as Eli Lilly’s Mounjaro, which is also available in India for type‑2 diabetes. The low price is intended to build early adoption and brand loyalty, giving Novo a competitive advantage before the market opens to generic competition.
Novo Nordisk India Managing Director Vikrant Shrotriya highlighted that Ozempic offers benefits beyond glycemic control, including weight loss and protection for cardiovascular and kidney health. He emphasized that the company’s pricing strategy is “judicious and competitive” in India, reflecting a commitment to broaden access while maintaining leadership in GLP‑1 therapies.
The launch of Ozempic, alongside the June 2025 introduction of Wegovy for chronic weight management, signals Novo Nordisk’s intent to strengthen its presence in India’s diabetes and obesity markets. The new product line is expected to generate a steady revenue stream, influence pricing dynamics, and position the company to capture market share before generic competitors enter the market. This strategic move underscores Novo Nordisk’s focus on expanding access to GLP‑1 therapy in emerging markets while protecting its competitive edge in the lead‑up to patent expiry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.